Valo Therapeutics names Michael Stein as CEO

Valo Therapeutics, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines, has appointed Dr Michael Stein to the full-time role of chief executive, having served as part-time co-chairman since inception in January 2017. The company is headquartered in Oxford, UK, and has a base in Helsinki, Finland.

Dr Stein’s career includes executive leadership and board roles with numerous University start-ups, most recently breaking the UK record for a seed round as CEO of OxStem, a biotechnology company focused on regenerative medicine which was spun-out of the University of Oxford in 2016. Another notable success includes the Map of Medicine which Dr Stein co-founded with UCL in 2001, taking it from start-up to a multi-million-pound exit to Informa plc in 2005 before it was sold to Hearst Inc. in 2008, where he continued to serve as EVP (Healthcare Innovation) until 2011.

Welcoming Dr Stein to the full-time post, the firm’s co-chairman Mattie Hautsalo said: “Michael is a highly experienced, international business leader who brings significant fundraising and partnering experience as well as immunological and medical expertise. We look forward to continuing to work with him to develop life changing treatments for cancer.